Can-Fite BioPharma to Showcase Late-Stage Pipeline and Licensing Deals at BIO 2026
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Can-Fite BioPharma ( (CANF) ) has issued an announcement.
On June 17, 2026, Can-Fite BioPharma announced it will present its late-stage clinical pipeline and licensing opportunities at the BIO International Convention 2026, held June 22–25 in San Diego. The company plans extensive partnering meetings with pharmaceutical and biotech companies to discuss licensing and commercialization of its Phase III and Phase II assets in oncology, liver and inflammatory indications.
Namodenoson is in a pivotal Phase III trial for advanced hepatocellular carcinoma, a Phase IIb study for MASH and a Phase IIa trial in pancreatic cancer, after receiving Orphan Drug Designation in the U.S. and Europe and Fast Track status in the U.S. for second-line HCC. Piclidenoson, which already delivered topline Phase III psoriasis data, is in a pivotal Phase III psoriasis trial and preparatory work is underway for a Phase II study in Lowe Syndrome.
The company’s A3AR-based drugs have shown a favorable safety profile in over 1,600 patients, supporting their positioning as orally administered therapies for cancer, liver and inflammatory diseases. Can-Fite has already secured multiple regional licensing deals generating about $20 million in upfront and milestone payments and aims to use BIO 2026 to expand strategic partnerships that could bring further milestones, royalties and broader global commercialization of its pipeline.
The most recent analyst rating on (CANF) stock is a Buy
with a $7.00 price target.
To see the full list of analyst forecasts on Can-Fite BioPharma stock,
see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and persistent cash burn) and bearish technical signals (price below key moving averages with negative MACD). Low leverage provides some risk mitigation, but valuation is not supportive given losses and no dividend data.
To see Spark’s full report on CANF stock,
click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an advanced clinical-stage biotechnology company developing proprietary small-molecule drugs targeting multi-billion-dollar markets in cancer, liver and inflammatory diseases. Its pipeline is built on an A3 adenosine receptor platform and includes lead candidates Namodenoson for hepatocellular carcinoma, MASH and pancreatic cancer, Piclidenoson for psoriasis and other inflammatory and rare diseases, and CF602 for erectile dysfunction.
Average Trading Volume: 490,002
Technical Sentiment Signal: Sell
Current Market Cap: $6.31M
Find detailed analytics on CANF stock on TipRanks’ Stock Analysis page.
